Assessment of patients requiring an ‘’as needed treatment’’ with alemtuzumab therapy for resumed Multiple Sclerosis (MS) disease activity following the second dose of alemtuzumab from a single MS Centre in the North East of England
By Dr Alyaa H.A. Eissa, Neurology registrar ST5, Newcastle upon Tyne Hospitals NHS Foundation Trust
Project poster
Project write up
More MS Academy Medication Projects
Natalizumab safety monitoring audit
By Zeinab Hamed, Speciality registrar, Sheffield teaching hospital
A Therapy led Sativex service – a retrospective audit of patient outcomes
By Jenny Thain, MS clinical specialist physiotherapist, The Walton Centre Liverpool
Siponimod use in Northern Ireland
By Conor Hughes, Clinical fellow, Royal Victoria Hospital
Encouraging excellence, developing leaders, inspiring change
MS Academy was established five years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.